Host transcriptome-guided drug repurposing for COVID-19 treatment: a meta-analysis based approach
Background Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared a pandemic by the World Health Organization, and the identification of effective therapeutic strategy is a need of the hour to combat SARS-CoV-2 infection. In this scenario, the drug repurposing approach is widely used for the rapid identification of potential drugs against SARS-CoV-2, considering viral and host factors. Methods We adopted a host transcriptome-based drug repurposing strategy utilizing the publicly available high throughput gene expression data on SARS-CoV-2 and other respiratory infection viruses. Based on the consistency in expression status of host factors in different cell types and previous evidence reported in the literature, pro-viral factors of SARS-CoV-2 identified and subject to drug repurposing analysis based on DrugBank and Connectivity Map (CMap) using the web tool, CLUE. Results The upregulated pro-viral factors such as TYMP, PTGS2, C1S, CFB, IFI44, XAF1, CXCL2, and CXCL3 were identified in early infection models of SARS-CoV-2. By further analysis of the drug-perturbed expression profiles in the connectivity map, 27 drugs that can reverse the expression of pro-viral factors were identified, and importantly, twelve of them reported to have anti-viral activity. The direct inhibition of the PTGS2 gene product can be considered as another therapeutic strategy for SARS-CoV-2 infection and could suggest six approved PTGS2 inhibitor drugs for the treatment of COVID-19. The computational study could propose candidate repurposable drugs against COVID-19, and further experimental studies are required for validation..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:8, p e9357 |
---|---|
Enthalten in: |
PeerJ - 8, p e9357(2020) |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Tamizhini Loganathan [VerfasserIn] |
---|
Links: |
doi.org [kostenfrei] |
---|
Themen: |
Biology (General) |
---|
doi: |
10.7717/peerj.9357 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
DOAJ008929629 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ008929629 | ||
003 | DE-627 | ||
005 | 20240414104242.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.7717/peerj.9357 |2 doi | |
035 | |a (DE-627)DOAJ008929629 | ||
035 | |a (DE-599)DOAJa08b8557bf3748c3996a755c8ce32ee0 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a QH301-705.5 | |
100 | 0 | |a Tamizhini Loganathan |e verfasserin |4 aut | |
245 | 1 | 0 | |a Host transcriptome-guided drug repurposing for COVID-19 treatment: a meta-analysis based approach |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Background Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared a pandemic by the World Health Organization, and the identification of effective therapeutic strategy is a need of the hour to combat SARS-CoV-2 infection. In this scenario, the drug repurposing approach is widely used for the rapid identification of potential drugs against SARS-CoV-2, considering viral and host factors. Methods We adopted a host transcriptome-based drug repurposing strategy utilizing the publicly available high throughput gene expression data on SARS-CoV-2 and other respiratory infection viruses. Based on the consistency in expression status of host factors in different cell types and previous evidence reported in the literature, pro-viral factors of SARS-CoV-2 identified and subject to drug repurposing analysis based on DrugBank and Connectivity Map (CMap) using the web tool, CLUE. Results The upregulated pro-viral factors such as TYMP, PTGS2, C1S, CFB, IFI44, XAF1, CXCL2, and CXCL3 were identified in early infection models of SARS-CoV-2. By further analysis of the drug-perturbed expression profiles in the connectivity map, 27 drugs that can reverse the expression of pro-viral factors were identified, and importantly, twelve of them reported to have anti-viral activity. The direct inhibition of the PTGS2 gene product can be considered as another therapeutic strategy for SARS-CoV-2 infection and could suggest six approved PTGS2 inhibitor drugs for the treatment of COVID-19. The computational study could propose candidate repurposable drugs against COVID-19, and further experimental studies are required for validation. | ||
650 | 4 | |a COVID-19 | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a Drug repurposing | |
650 | 4 | |a Host transcriptome | |
653 | 0 | |a Medicine | |
653 | 0 | |a R | |
653 | 0 | |a Biology (General) | |
700 | 0 | |a Srimathy Ramachandran |e verfasserin |4 aut | |
700 | 0 | |a Prakash Shankaran |e verfasserin |4 aut | |
700 | 0 | |a Devipriya Nagarajan |e verfasserin |4 aut | |
700 | 0 | |a Suma Mohan S |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t PeerJ |d PeerJ Inc., 2013 |g 8, p e9357(2020) |w (DE-627)DOAJ000007528 |x 21678359 |7 nnns |
773 | 1 | 8 | |g volume:8, p e9357 |g year:2020 |
856 | 4 | 0 | |u https://doi.org/10.7717/peerj.9357 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/a08b8557bf3748c3996a755c8ce32ee0 |z kostenfrei |
856 | 4 | 0 | |u https://peerj.com/articles/9357.pdf |z kostenfrei |
856 | 4 | 0 | |u https://peerj.com/articles/9357/ |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2167-8359 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_DOAJ | ||
951 | |a AR | ||
952 | |d 8, p e9357 |j 2020 |